Page 77 - Priority Review News Today

WESTON (dpa-AFX) - Eisai Co., Ltd. and Biogen Inc. (BIIB) said that an application for manufacturing and marketing approval for an anti-amyloid-? (A?) protofibril antibody, lecanemab (generic name

STOCKHOLM, Jan. 30, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...

TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts

/PRNewswire/ -- BioArctic ABs (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the application for manufacturing and marketing approval...

TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq:...

(RTTNews) - Eisai Co., Ltd. and Biogen Inc. (BIIB) said that an application for manufacturing and marketing approval for an anti-amyloid-ß (Aß) pr...

30.01.2023 - SHANGHAI and CAMBRIDGE, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) - Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted priority ... Seite 1

Lecanemab Receives Priority Review Status in Japan - read this article along with other careers information, tips and advice on BioSpace

The FDA has accepted for Priority Review the sNDA for avapritinib for the treatment of indolent systemic mastocytosis in adults.

Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation - read this article along with other careers information, tips and advice on BioSpace